Supplementary Figures 1-8 from Mesenchymal and MAPK Expression Signatures Associate with Telomerase Promoter Mutations in Multiple Cancers | CU Experts

<p>Fig. S1. Projecting the individual TERTp mutations transcriptional signatures on top of the Onco-GPS map of cellular states (Kim et al. 2017). Fig.S2. Association between the different mRNA signatures analyzed in this study. Fig S3. Expression of epithelial and mesenchymal markers in TERTp mutants (TPM) and wild-type (wt) cancer cell lines. Fig S4. CDH1 expression levels in CCLE lines. Fig S5. GABPa and GABPb1 expression by tissue type. Fig S6. Stratification of TERTp mutant cell lines in The Cancer Therapeutics Response Portal (CTRP) by BRAF status reveals inhibition of growth in the absence of BRAF mutation. Fig. S7. Representative immunoblots of TERT promoter cell lines treated with trametinib for 24 hours.</p>

Stern JL; Hibshman G; Hu K; Ferrara SE; Costello JC; Kim W; Tamayo P; Cech TR; Huang FW

VIVO